

Press release

Baar, 30 June 2008

Annual General Meeting of HBM BioVentures Ltd All Board of Directors proposals approved

Shareholders at today's Annual General Meeting of HBM BioVentures Ltd passed all of the motions put forward by the Board of Directors. Prof. Dr. Heinz Riesenhuber and Dr. Karl W. Preisig were re-elected to the Board, and Dr. Eduard Holdener was appointed as a new member.

"Our portfolio of companies contains a profit potential that is not currently reflected in our share price. Our Management will do all it can to ensure that HBM BioVentures shares are traded at a realistic price. The Board of Directors has mandated the Management to prepare a program firstly to acquire up to CHF 100 million of the company's own shares with the aim of recommending their cancellation to the Annual General Meeting, secondly, to make an annual nominal value repayment to shareholders, corresponding to an annual bond yield. In addition, a focused communications campaign shall contribute to the clarification and the better understanding of the prospects for success of the HBM BioVentures portfolio," said Dr. Henri B. Meier, Chairman of the Board of Directors of HBM BioVentures. "In this connection it is particularly important to time such measures correctly."

HBM's shareholders approved the re-election of two directors, Prof. Dr. Heinz Riesenhuber and Dr. Karl W. Preisig, for a further term of three years, and elected Dr. Eduard E. Holdener to the Board. Dr. Holdener was a member of the Corporate Executive Committee of Roche Holding, with responsibility for pharmaceutical drug development, until the end of 2007.

The Annual General Meeting also approved the revised articles of association, including the deletion of the section on the authorised capital that expired in March 2008 and the amendments based on the new law on audit companies. The shareholders voted in favour of moving the company's registered office from Baar to Zug.

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, joachim.rudolf@hbmbioventures.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Brief profile of HBM BioVentures Ltd

HBM BioVentures invests globally in the human medicine / biotechnology and medical technology sectors. As a venture capital company it manages a mature, widely diversified portfolio of private and emerging small-cap public companies. Investors value HBM BioVentures as an integral part of their healthcare portfolio, giving them access to this newly created investment segment with its high value creation potential. HBM BioVentures is an active, long-term investor in research and development which finances, accompanies and supports portfolio companies as a key partner. With net assets of approx. CHF 1 billion, HBM BioVentures is one of the most liquid investments in this sector. Lean structures ensure a competitive cost structure, while wide-ranging expertise, operating industrial experience, high professional standards and transparency distinguish the company. HBM BioVentures Ltd has a broad shareholder base and is listed on the SWX Swiss Exchange (Ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SWX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation. A public share offer in the USA would be conducted by means of a prospectus that would be available from HBM BioVentures Ltd and would contain detailed information about the Company and its management, as well as the annual financial statements.

HBM BioVentures Ltd
Grabenstrasse 25
CH-6340 Baar / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com